Digital tools key to immuno-oncology’s future: report
If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper.
The whitepaper, ‘The Role of Digital Health in Immuno-oncology Therapy Development and Adoption’ from BrightInsight, highlights the many ways in which digital can realise and accelerate the impact of innovative immuno-oncology (IO) therapies.
It says that the growth in treatment options is making it more difficult for oncologists to match patients to the right therapy – but there are many ways in which digital tools can help address this by leveraging data.
“Increasing the accuracy of patient matching – by getting the right patient the right therapy and maximising adherence – could have greater impact on clinical outcomes than more primary innovation with new therapies,” the authors point out.
Companion digital diagnostics and clinician support tools – aided by predictive AI algorithms – can help doctors sort through data and decide which IO medicines will work best for a particular patient, ultimately allowing for more precision treatment.
• Read the full article in pharmaphorum's Deep Dive digital magazine
